

REVIEW

Open Access



Advances in redox-responsive drug delivery systems of tumor microenvironment

Xiaoshuang Guo¹, Yuan Cheng¹, Xiaotian Zhao¹, Yanli Luo², Jianjun Chen^{3*} and Wei-En Yuan^{1*}

Abstract

With the improvement of nanotechnology and nanomaterials, redox-responsive delivery systems have been studied extensively in some critical areas, especially in the field of biomedicine. The system constructed by redox-responsive delivery can be much stable when in circulation. In addition, redox-responsive vectors can respond to the high intracellular level of glutathione and release the loaded cargoes rapidly, only if they reach the site of tumor tissue or targeted cells. Moreover, redox-responsive delivery systems are often applied to significantly improve drug concentrations in targeted cells, increase the therapeutic efficiency and reduce side effects or toxicity of primary drugs. In this review, we focused on the structures and types of current redox-responsive delivery systems and provided a comprehensive overview of relevant researches, in which the disulfide bond containing delivery systems are of the utmost discussion.

Keywords: Redox-responsive, Drug delivery system, Antitumor, Disulfide bond

Background

In tumor therapy, developing a safe and efficient drug delivery system is a key factor to the success. With the rapid development of nanotechnology and materials, nano-carriers have been gradually applied in drug and gene delivery [1]. Antitumor nano drug delivery systems (ATNDDS) have been widely studied in recent years [2]. ATNDDS can improve the solubility and stability of drugs, enhance the targeting ability, reduce potential toxicity, achieve the co-delivery of drugs and genes, and realize the collaborative treatment [3]. In addition, it was reported that ATNDDS could be developed to alleviate the problem of drug resistance in cancer therapy [3].

Tumor tissues show different cellular microenvironments (e.g. acidic environments, enzyme environments, and reducing environments) for their unique physiological characteristics [4]. Developing nano-carriers that could respond to these unique physiological

microenvironments was found to be a good way to release cargoes rapidly after entering cells [5, 6]. When the concentration of cargoes in cells reached a certain threshold, tumor cells could be effectively killed. In recent years, a great progress has been made in developing redox-responsive nano-carriers. This review provides a comprehensive overview in relevant researches, and focuses on the structures and types of redox-responsive delivery systems containing disulfide bonds.

The reducing environment of tumor cells

The reducing environment of tumor cells is strictly controlled and mainly determined by the reduction and oxidation states of NADPH/NADP⁺ and glutathione (GSH, GSH/GSSG), both of which have different reduction potentials and capacities [7]. In a reducing environment, concentration of GSH is higher than that of NADPH, in which case GSH plays a major role in the regulation of the microenvironment. At molecular levels, GSH controls the cellular reducing environment mainly through the formation and fragmentation of disulfide bonds and the reaction with excess ROS. And this is why the concentration of GSH is typically regarded as a proxy for the cellular reducing environment [8, 9]. The intracellular concentration of GSH can reach 10 mM, while

*Correspondence: jchen21@smu.edu.cn; yuanweien@sjtu.edu.cn

¹ Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan RD, Shanghai 200240, China

³ School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou, China

Full list of author information is available at the end of the article



the extracellular concentration of that ranges from 2 to 20 μM [10]. It was reported that the concentration of GSH in tumor tissues was at least 4-fold higher than that in normal tissues, and was especially high in some multi-drug resistant tumors [11, 12]. Through these mechanisms, we could find that the differences in reducibility of the environments between normal and tumor cells provide a potentially feasible strategy for targeted therapy with the help of redox-responsive ATNDDS [13].

Redox-responsive delivery systems

The reducing environment of tumors serve as a unique internal signal that allows redox-responsive nanocarriers to degrade in tumor cells and release loaded cargoes. There are mainly three advantages of redox-responsive nanocarriers. First, they are often stable in normal tissues, which can obviously reduce the biological toxicity and side effects of both carriers and cargoes. Second, they show a prompt response to high GSH concentration in tumor cells to release cargoes (usually a few minutes to hours). Finally, compared to other potential sites of cargo release, the release in cytoplasm is often expected to have better therapeutic effects [11, 14]. In this review, we summarized currently existing redox-responsive carriers into the following categories based on their differences in structure.

Redox-responsive delivery systems with disulfide bonds

Redox-responsive delivery systems with disulfide bonds are well studied in many researches. Disulfide bonds can be easily broken down by reducing glutathione into sulfhydryl groups, which causes the degradation of carriers and facilitates the release of cargoes. The specific application of this kind of delivery system is described in details in the following context.

Redox-responsive delivery systems with diselenide bonds

With many studies on the redox-responsiveness of disulfide bonds going on, diselenide bonds are attracting much attention as well. Diselenide bonds have similar reduction sensitivity and redox-responsive ability as that of disulfide bonds [15, 16]. As the Se–Se bond and C–Se bond are with lower bond energy than that of S–S bonds (Se–Se 172 kJ/mol; C–Se 244 kJ/mol; S–S 268 kJ/mol), a more sensitive redox-responsive delivery system can be designed with the use of diselenide bonds in tumor therapy [17, 18].

Gang Cheng et al. added the active ester containing diselenide bonds to the branched oligoethyleneimine 800 Da (OEI_{800}) to synthesize the polycationic carrier $\text{OEI}_{800}\text{-SeSe}_x$ [19]. The results showed that $\text{OEI}_{800}\text{-SeSe}_x$ and $\text{OEI}_{800}\text{-SS}_x$ shared similar redox-responsive degradation properties, and their cytotoxicity was significantly

lower than that of PEI_{25k} . Besides that, the transfection efficiency of both $\text{OEI}_{800}\text{-SeSe}_x$ and $\text{OEI}_{800}\text{-SS}_x$ was significantly higher than that of OEI_{800} . However, the selenium-containing system is still in its infancy owing to its poor solubility and stability, which remains an unsolved problem for existing synthetic methods [20].

Other redox-responsive delivery systems

In addition to disulfide and diselenide bonds, there are still some studies on other redox-responsive chemical structures. For example, succinimide-thioether linkage is sensitive to reducing environments and can be cleaved by exogenous glutathione to achieve rapid intracellular release [21]. When compared to that of disulfide bonds, succinimide-thioether linkage showed a higher blood stability and slower cargo release.

Delivery systems with “trimethyl-locked” benzoquinone (TMBQ) are also sensitive to reducing environments, which were reported to deliver drugs to solid tumors [22, 23]. With the reduction of $\text{Na}_2\text{S}_2\text{O}_4$, TMBQ is detached from the backbone, resulting in the degradation of nanoparticles. In vitro drug release experiments showed that this novel delivery system can release 52% of the drug in 3 h in the presence of $\text{Na}_2\text{S}_2\text{O}_4$. However, the reduction concentration of sodium salicylate used in the experiments was relatively higher compared to the intracellular concentration of GSH. Therefore, the exact release capacity of delivery systems with TMBQ in tumor cells is still unclear and needs to be further explored in future studies.

Application of disulfide bonds in redox-responsive delivery systems


Delivery systems with disulfide bonds can be cleaved in high concentration of GSH, with which the carrier could degrade rapidly to release cargoes. Current applications of disulfide bonds in redox-responsive delivery systems are mainly composed of the use of disulfide bonds as linkers and cross-linking agents (as shown in Fig. 1) [20].

Disulfide bonds acting as linkers

Disulfide bonds are often used in delivery systems as linkers, which can degrade rapidly to release cargoes in the reducing environment of GSH in tumor cells. This responsive bond can be attached to the backbone of polymers and used in the conjugation of side chains or nanoparticles with drugs, genes, and targeting groups.

Disulfide bonds present in the backbone

In the GSH reducing environment, carriers with disulfide bonds in the backbone (Fig. 1a) are depolymerized at a faster rate than other types of redox-responsive carriers. The delivery system with disulfide bonds in the backbone



can be further divided to two categories: monomers containing disulfide bonds and monomers containing sulfhydryl groups. However, the stability of this structure (disulfide bond) is not as good as other categories, and it is difficult to be modified structurally. Therefore, this type of carriers with high content of disulfide bonds were studied less extensively.

Polymeric carriers synthesized from disulfide-containing monomers are composed of many repeating units, which means the disulfide bond occupies a relatively high proportion throughout the polymer system. Therefore, when encountering the reducing environment, the polymer is with a high degree of response and degrades, after which cargoes will be released completely. Disulfide-containing fragments commonly used in polymers include cystamine [24], cystine [25], SPDP

(*N*-succinimidyl-3-(2-pyridyldithiol) propionate) [26], DSDMA (disulfide-based dimethacrylate) [27] and other structures (Fig. 2). For example, David Oupický and his co-workers utilized *N,N'*-cystaminebisacrylamide (CBZ) and 1-(2-Aminoethyl) piperazine (AEPZ) as raw materials to synthesize reducible PAA (rPAA) (Fig. 3) [28]. And then they compared rPAA with poly(amido amines) (PAA) in cellular experiments, which share similar structures. It was demonstrated that in all tested cell lines, rPAA with high content of disulfide bonds is less cytotoxic than PAA, and rPAA released cargoes at a faster rate and can silence the luciferase gene more rapidly.

Due to the immaturity of mercapto polymerization, there are few researches about this method currently. Therefore, existing delivery systems that are based on the mercapto polymerization are very rare. There was a study




Fig. 2 Disulfide-containing fragments commonly used in polymers




Fig. 3 Synthetic scheme of rPAA and PAA (Reprinted with permission from [28]. Copyright 2010 Elsevier)

utilizing mercapto polymerization to modify spermine with thiolate, and a gene carrier named bioreducible poly-spermine (BPS) with linear structures was successfully synthesized [29]. Different BPS with various molecular weight (27.5 kDa, 15.7 kDa and 6.1 kDa) were analyzed in this study. It was found that the cytotoxicity of all BPS was significantly lower, and they were with higher

transfection efficiency, compared to that of PEI 25k (control group).

Disulfide bonds present in side chains

Disulfide bonds present in side chains are usually used to modify the main chain (Fig. 1b). Attaching targeting groups to the backbone can increase the selectivity

of carriers. Hydrophobic backbone connecting hydrophilic structures [30] or hydrophilic backbone connecting hydrophobic structures [31, 32] can promote the formation of micelles. In addition, side chains can also be linked to drugs to promote drug delivery [33, 34]. Redox-responsive delivery systems with disulfide bonds present in side chains are more multi-functional and easier to be chemically modified compared to those with disulfide bonds in the backbone.

A study utilized progressive ring-opening reactions of polysuccinimide (PSI) to prepare a redox and pH dual stimuli-responsive poly(aspartic acid) derivative to control the release of drugs [30]. Polyaspartamide backbone grafted polyethylene glycol (PEG) chains through redox-responsive disulfide bonds, forming a sheddable shell for the micelles when in reducing environment. The results showed that the dual responses to both acidic and reducing environment could enhance drug release, and it was found that the DOX-loaded micelles showed low cytotoxicity.


Recently, it was reported that linking the hydrophobic structure of deoxycholic acid (DOCA) to the hydrophilic hyaluronic acid (HA) backbone via disulfide bonds can be used to synthesize the redox-responsive carrier HA-ss-DOCA for paclitaxel (PTX) targeted intracellular delivery [31]. The results showed that PTX-loaded HA-ss-DOCA micelles could release drugs rapidly inside the cells and the endocytosis mediated by HA-receptors could enhance the drug accumulation at tumor sites. There was another study introducing a chitosan based glycolipid-like nanocarrier (CSO-ss-SA) through the link between the hydrophobic structure and the hydrophilic backbone with disulfide bonds to realize the co-delivery of siRNA and drugs (Fig. 4) [32, 35]. In the study, the model drug Nile Red was released 8–11 h later than siRNA, which achieved the synergistic treatment of genes and drugs.

Connecting cisplatin to the PLG chains through disulfide bonds can be utilized to synthesize novel redox-responsive micelles consisting of polyethylene glycol-poly-(L-glutamic acid) (PEG-PLG) [33]. The micelles in this study showed well-controlled cisplatin loading yield, excellent redox-responsive drug release kinetics, stronger antitumor activity and less biological toxicity.

Disulfide bonds attached to the surface of nanoparticles

Nowadays the technology of nanoparticles is becoming more and more mature (Fig. 1c), with different nanoparticles studied extensively including magnetic nanoparticles (Fe_3O_4) [36], gold nanoparticles [37, 38], Ag nanoparticles [39], silica nanoparticles [40–44], gold/mesoporous silica hybrid nanoparticles (GoMe) [45], and mesoporous manganese silicate coated silica nanoparticles (MMSSN) [46]. Among them, mesoporous silica nanoparticles (MSN) have been well studied. Utilizing disulfide bonds to link modified structures to nanoparticles' surface can enrich the function of nanoparticles [43], such as enhancing the redox-responsiveness and targeting capabilities [42]. In addition, disulfide bonds can be linked with genes or drugs [41], which can realize the rapid release of genes or drugs under reducing environments.

Ham linked transferrin (Tf) as both a capping agent and a targeting group on the surface of MSNs via redox-responsive disulfide bonds, which could encapsulate doxorubicin (DOX) efficiently [42]. When the system is exposed to GSH, DOX can burst out. The system has excellent biocompatibility, accumulation in tumor cells and significant enhancement of targeting. In another study, disulfide bonds were utilized to attach siRNA to the surface of MSNs, which realized the co-delivery of DOX and siRNA [41]. The results showed that MSNs-SS-siRNA@Dox significantly enhanced the antitumor activity and achieved satisfactory therapeutic effects on tumor inhibition both in vitro and in vivo.



Disulfide bonds linking two moieties

Disulfide bonds can also link two moieties together even they are with different roles (Fig. 1d) [47], which is a good strategy to make the structure and function of carriers more abundant [48]. Linking two polymers which are hydrophilic and hydrophobic respectively via disulfide bonds can form an amphiphilic copolymer and then self-assemble into micelles [49–52], which can deliver hydrophobic drugs and improve their solubility.

Both the premature release of cargoes when the carrier is still in blood circulation and insufficient intracellular drug release are critical issues to be solved. Li et al. introduced three disulfide bonds into the amphiphilic poly(ethylene glycol)-polycaprolactone copolymer blocks to synthesize triple-sensitive cleavable polymeric nano-carrier mPEG-SS-PCL-SS-PCL-SS-mPEG (tri-PESC), which was demonstrated to be a good way to improve the sensitivity to narrow the range of GSH concentration (Fig. 5) [47]. Tri-PESC NPs remain intact when in blood circulation due to stable disulfide bonds, whereas the loaded drugs are effectively released when encountering tumor cells with high GSH concentration. Another study used disulfide linkers to connect pH-responsive p(His)_n block with biocompatible phospholipid analog poly(2-methacryloyloxyethyl phosphorylcholine) [p(MPC)] block to create a pH/redox dual stimuli-responsive block copolymer [50]. The block copolymers are self-assembled into uniform micelles to encapsulate DOX effectively and enhance drug release and antitumor activity.

Disulfide bonds acting as cross-linking agents

At present, micelles assembled by the amphiphilic diblock or triblock copolymer are extensively studied. Due to the complexity of in vivo environment, micelles often have a poor stability in the delivery process, which easily lead to the loss of drugs. Furthermore, unexpected side effects may be caused in this case. To solve this problem, crosslinked micelles are often used to enhance the stability and thus the loss of cargoes could be effectively prevented before reaching cells or other target sites. Meanwhile, the crosslinked structure may also act as barriers to drug release, slowing down the rate of release. Disulfide bonds exist mainly in the core-shell form of micelles as cross-linkers, such as shell crosslinked micelles (SCM, Fig. 1e) [53] and core crosslinked micelles (Fig. 1f) [54, 55]. With the rapid response of disulfide bonds to the reducing environment, the release of the drug can be promoted.

Lee et al. designed a redox-responsive shell-crosslinked micelle. Two low toxicity materials, poly-(ethylene glycol) (PEG) and polyamino acid, were chosen to self-assemble the triblock copolymer poly(ethylene glycol)-b-poly(L-lysine)-b-poly(L-phenylalanine) (PEG-b-PLys-b-Ppha) [53]. The use of disulfide cross-linking in the middle shell enhanced the stability of micelles. It was demonstrated that shell cross-linking could significantly improve the physical stability of micelles. With the increase of the degree of crosslinking, the polyplex can slow down the release of methotrexate (MTX) more effectively.




Fig. 5 Schematic representation of redox-responsive tri-PESC micelles (Reprinted with permission from [47]. Copyright 2016 John Wiley and Sons)

The Diels–Alder click-type reaction can be utilized to synthesize a redox-responsive core cross-linked micelles poly(ethylene oxide)-*b*-poly(furfuryl methacrylate) (PEO-*b*-PFMA), which encapsulated DOX in the hydrophobic core (Fig. 6) [54]. Results showed that the core cross-linked micelles could enhance the stability of the micelle under physiological conditions. While under the environment of DTT, the disulfide bonds rapidly broke down, which caused micellar dissociation and released DOX.

Disulfide bonds in other redox-responsive delivery systems

There are some other redox-responsive delivery systems containing disulfide bonds, such as polymeric nanogel with disulfide linkages [56, 57], liposome [58, 59], dendrimer–drug conjugates with disulfide linkages [60] and other structures. However, currently no much work is done on this topic, and thus detailed applications are not discussed here.

Conclusion

The reducing environment in tumor cells has appeared as a natural stimulus for effective intracellular delivery for many years. Redox-responsive drug delivery systems have been recognized as a valuable strategy to achieve efficient intracellular drug delivery with low cytotoxicity. Utilizing the differences between the special microenvironments of tumor cells and normal cells, redox-responsive delivery systems can meet the requirement of targeted therapy in theory. With various reducing structures or functional groups being added, the redox-responsive system is moving in the direction of low toxicity and high efficiency. However, some studies have reported that the reduction of thiolated polymers takes several hours under physiological reducing conditions, which may be a future barrier to overcome [61, 62].

In fact, there exists multiple unique stimuli in tumor microenvironment such as pH, enzymes, and oxidants, while many other external stimuli could also utilized including magnetic field, temperature, light and ultrasound [10, 63, 64]. In addition to the reduction property




Fig. 6 Schematic representation of the core crosslinked micelles and morphology transition under DTT reduction (Reprinted with permission from [54]. Copyright 2016 J John Wiley and Sons)

in tumor microenvironment, other features could be further developed like abundant enzymes in the lysosomes and slightly lower pH in the endosomes and lysosomes. The pH-responsive drug carriers can be degraded under endo/lysosomal pH conditions, which contributes to the effective drug release. However, the chemical cleavage of a pH-responsive substructure is not fast enough, resulting in slow response speed [62]. Recent studies have reported that tumor cells not only acidify but also alkalize, in which situation pH-responsive drug delivery systems do not apply [65, 66]. Enzyme-responsive drug delivery systems have been recognized as a valuable strategy to achieve efficient intracellular drug delivery [67, 68], as there are abundant enzymes including proteases, matrix metalloproteinases and hyaluronidases in the lysosomes [62]. Despite the fact that enzyme-responsive drug delivery systems have high specificity, the complicated synthesis methods and harsh lysosomal conditions leading to drug degradation limit their feasibility in application [14].

Therefore, the delivery systems which can respond to multiple stimuli have become a popular strategy of current research, because they are safer and more targeted than delivery systems with one stimulus [40, 43, 59, 69, 70]. The development of advanced gene/drug or multidrug codelivery systems with stimuli-responsive release manner for tumor therapy is also desirable [38, 71]. However, combining multiple functions into one delivery system remains a challenge. For example, in order to visualize drug delivery and release, combining imaging technique and therapy will facilitate the study of drug distribution and controlled release simultaneously [20], which is difficult to be achieved currently. Moreover, MDR (multi-drug resistance) leading to low clinical anticancer efficacy remains a complicated problem to be solved [34, 52, 72]. In addition, delivery systems with multiple functions while being simple in structure and delivery systems with specific structures while being less cost are often contradictory.

Even so, many novel intracellular environment-responsive drug delivery systems have been reported, and their structure and function are constantly being improved. It is believed that with the continuous development of materials science and tumor treatment, problems mentioned above can be effectively solved by the development of “smart” drug delivery systems such as the redox-responsive system.

Abbreviations

ATNDDS: antitumor nano drug delivery systems; NADPH: nicotinamide adenine dinucleotide phosphate; GSH: glutathione; ROS: reactive oxygen species; MDR: multi-drug resistance; TMBQ: “trimethyl-locked” benzoquinone;

SPDP: *N*-succinimidyl-3-(2-pyridyldithiol) propionate; DSDMA: disulfide-based dimethacrylate; CBZ: *N,N'*-cystaminebisacrylamide; AEPZ: 1-(2-aminoethyl) piperazine; BPS: bio-reducible polyspermine; PEI: polyetherimide; PSI: polysuccinimide; PEG: polyethylene glycol; HA: hydrophilic hyaluronic acid; DOCA: deoxycholic acid; PTX: paclitaxel; PEG-PLG: polyethylene glycol-poly(L-glutamic acid); Fe₃O₄: magnetic nanoparticles; GoMe: gold/mesoporous silica hybrid nanoparticles; MMSSN: mesoporous manganese silicate coated silica nanoparticles; MSN: mesoporous silica nanoparticles; Tf: transferrin; DOX: doxorubicin; tri-PESC: mPEG-SS-PCL-SS-PCL-SS-mPEG; RAFT: reversible addition-fragmentation chain transfer; ROP: ring-opening polymerization; p(MPC): poly(2-methacryloyloxyethyl phosphorylcholine); SCM: shell crosslinked micelles; PEG-b-PLys-b-Ppha: poly(ethylene glycol)-b-poly(L-lysine)-b-poly(L-phenylalanine); MTX: methotrexate; PEO-b-PFMA: poly(ethylene oxide)-b-poly(furfuryl methacrylate).

Authors' contributions

WY conceived the initial idea, the conceptualization, and the study design, and participated in the data extraction and analysis. JC and WY revised the manuscript. XG, YC, XZ, YL, and JC participated in the study design, searched databases, extracted and assessed studies and helped draft the manuscript. XG wrote the manuscript. All authors read and approved the final manuscript.

Author details

¹ Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan RD, Shanghai 200240, China. ² Department of Pathology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yi-Shan Road, Shanghai 200233, People's Republic of China. ³ School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou, China.

Acknowledgements

The study was supported by the Projects of National Science Foundation of China (Nos. 81570992, and 81602099), SUMHS seed foundation project (No. HMSF-16-21-010), Science and Technology Development Foundation of Pudong New District, Shanghai, China (Nos. PKJ2016-Y55 and PWZxq2017-03), and National Science and Technology Major Projects for “Major New Drugs Innovation and Development” (2018ZX09711003-008-002). The study was also partly sponsored by the Interdisciplinary Program of Shanghai Jiao Tong University (YG2017MS22, YG2015QN12, YG2017QN56 and YG2016QN22), scientific research project of high level talents (No. C1034335) in Southern Medical University of China, and Thousand Youth Talents Program (No. C1080094) from the Organization Department of the CPC Central Committee. We appreciate the help from faculties of Instrumental Analysis Centre (IAC) of Shanghai Jiao Tong University.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Not applicable.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Funding

No funding was available for this publication.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 22 April 2018 Accepted: 11 September 2018
Published online: 22 September 2018

References

- Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. *Nat Rev Cancer*. 2017;17:20.
- Chen BL, Dai WB, He B, Zhang H, Wang XQ, Wang YG, Zhang Q. Current multistage drug delivery systems based on the tumor microenvironment. *Theranostics*. 2017;7:538–58.
- Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine therapeutic approaches to overcome cancer drug resistance. *Adv Drug Deliv Rev*. 1866;2013:65.
- Cheng R, Meng F, Deng C, Zhong Z. Bioresponsive polymeric nanotherapeutics for targeted cancer chemotherapy. *Nano Today*. 2015;10:656–70.
- Kaur S, Prasad C, Balakrishnan B, Banerjee R. Trigger responsive polymeric nanocarriers for cancer therapy. *Biomater Sci*. 2015;3:955–87.
- Liu L, Liu P. Synthesis strategies for disulfide bond-containing polymer-based drug delivery system for reduction-responsive controlled release. *Front Mater Sci*. 2015;9:211–26.
- Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. *J Nutr*. 2004;134:489.
- Such GK, Yan Y, Johnston APR, Gunawan ST, Caruso F. Interfacing materials science and biology for drug carrier design. *Adv Mater*. 2015;27:2278–97.
- Aon MA, Cortassa S, O'Rourke B. Redox-optimized ROS balance: a unifying hypothesis. *Biochim Biophys Acta*. 2010;1797:865–77.
- Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. *Nat Mater*. 2013;12:991–1003.
- Meng F, Hennink WE, Zhong Z. Reduction-sensitive polymers and bioconjugates for biomedical applications. *Biomaterials*. 2009;30:2180.
- Li R, Xie Y. Nanodrug delivery systems for targeting the endogenous tumor microenvironment and simultaneously overcoming multidrug resistance properties. *J Control Release*. 2017;251:49–67.
- Lu Y, Aimetti AA, Langer R, Gu Z. Bioresponsive materials. 2016;1:16075.
- Meng F, Cheng R, Deng C, Zhong Z. Intracellular drug release nanosystems. *Mater Today*. 2012;15:436–42.
- Beld J, Woycechowsky KJ, Hilvert D. Selenogluthathione: efficient oxidative protein folding by a diselenide. *Biochemistry*. 2007;46:5382–90.
- Zhou YJ, Jie KC, Huang FH. A redox-responsive selenium-containing pillar 5 arene-based macrocyclic amphiphile: synthesis, controllable self-assembly in water, and application in controlled release. *Chem Commun*. 2017;53:8364–7.
- Zhai S, Hu X, Hu Y, Wu B, Xing D. Visible light-induced crosslinking and physiological stabilization of diselenide-rich nanoparticles for redox-responsive drug release and combination chemotherapy. *Biomaterials*. 2017;121:41–54.
- Ji S, Cao W, Yu Y, Xu H. Dynamic diselenide bonds: exchange reaction induced by visible light without catalysis. *Angew Chem*. 2014;53:6781.
- Cheng G, He Y, Xie L, Nie Y, He B, Zhang Z, Gu Z. Development of a reduction-sensitive diselenide-conjugated oligoethylenimine nanoparticulate system as a gene carrier. *Int J Nanomed*. 2012;7:3991–4006.
- Huo M, Yuan J, Tao L, Wei Y. Redox-responsive polymers for drug delivery: from molecular design to applications. *Polym Chem*. 2014;5:1519–28.
- Baldwin AD, Kiick KL. Reversible maleimide-thiol adducts yield glutathione-sensitive poly(ethylene glycol)-heparin hydrogels. *Polym Chem*. 2013;4:133–43.
- Cho H, Bae J, Garripelli VK, Anderson JM, Jun HW, Jo S. Redox-sensitive polymeric nanoparticles for drug delivery. *Chem Commun*. 2012;48:6043–5.
- Levine MN, Raines RT. Trimethyl lock: a trigger for molecular release in chemistry, biology, and pharmacology. *Chem Sci*. 2012;3:2412.
- Li Y, Lokitz BS, Armes SP, McCormick CL. Synthesis of reversible shell cross-linked micelles for controlled release of bioactive agents. *Macromolecules*. 2006;39:2726–8.
- Wu J, Zhao L, Xu X, Bertrand N, Choi WI, Yameen B, Shi J, Shah V, Mulvale M, Maclean JL. Hydrophobic cysteine poly(disulfide)-based redox-hyper-sensitive nanoparticle platform for cancer theranostics. *Angew Chem*. 2015;54:9218–23.
- Vachutinsky Y, Oba M, Miyata K, Hiki S, Kano MR, Nishiyama N, Koyama H, Miyazono K, Kataoka K. Antiangiogenic gene therapy of experimental pancreatic tumor by sFlt-1 plasmid DNA carried by RGD-modified crosslinked polyplex micelles. *J Control Release*. 2011;149:51–7.
- Zhang L, Liu W, Lin L, Chen D, Stenzel MH. Degradable disulfide core-cross-linked micelles as a drug delivery system prepared from vinyl functionalized nucleosides via the RAFT process. *Biomacromol*. 2008;9:3321.
- Manickam DS, Li J, Putt DA, Zhou QH, Wu C, Lash LH, Oupický D. Effect of innate glutathione levels on activity of redox-responsive gene delivery vectors. *J Control Release*. 2010;141:77–84.
- Park H, Nichols JW, Kang HC, Bae YH. Bioreducible polyspermine as less toxic and efficient gene carrier. *Polym Adv Technol*. 2014;25:545–51.
- Gong C, Shan M, Li B, Wu G. A pH and redox dual stimuli-responsive poly(amino acid) derivative for controlled drug release. *Colloids Surf B*. 2016;146:396–405.
- Li J, Huo M, Wang J, Zhou J, Mohammad JM, Zhang Y, Zhu Q, Waddad AY, Zhang Q. Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. *Biomaterials*. 2012;33:2310–20.
- Hu Y, Liu N, Cheng B, Tan Y, Wen L, Yuan H, Hu F. Sequential delivery of therapeutic agents using a rationally designed disulfide-linked glycolipid-like nanocarrier. *Oncotarget*. 2016;7:83258–69.
- Wang Z, Liu H, Shu X, Zheng L, Chen L. A reduction-degradable polymer prodrug for cisplatin delivery: preparation, in vitro and in vivo evaluation. *Colloids Surf B*. 2015;136:160–7.
- Zhou Y, Wang S, Ying X, Wang Y, Geng P, Deng A, Yu Z. Doxorubicin-loaded redox-responsive micelles based on dextran and indomethacin for resistant breast cancer. *Int J Nanomed*. 2017;12:6153–68.
- Hu Y-W, Du Y-Z, Liu N, Liu X, Meng T-T, Cheng B-L, He J-B, You J, Yuan H, Hu F-Q. Selective redox-responsive drug release in tumor cells mediated by chitosan based glycolipid-like nanocarrier. *J Controlled Release*. 2015;206:91–100.
- Zhang L, Li Y, Yu JC, Chan KM. Redox-responsive controlled DNA transfection and gene silencing based on polymer-conjugated magnetic nanoparticles. *RSC Advances*. 2016;6:72155–64.
- Belbekhouche S, Reinicke S, Espeel P, Du Prez FE, Eloy P, Dupont-Gillain C, Jonas AM, Demoustier-Champagne S, Glinel K. Polythiolactone-based redox-responsive layers for the reversible release of functional molecules. *ACS Appl Mater Interfaces*. 2014;6:22457–66.
- Ghorbani M, Hamishehkar H. Redox and pH-responsive gold nanoparticles as a new platform for simultaneous triple anti-cancer drugs targeting. *Int J Pharm*. 2017;520:126.
- Qiu L, Zhao L, Xing C, Zhan Y, Qiu L, Zhao L, Xing C, Zhan Y. Redox-responsive polymer prodrug/AgNPs hybrid nanoparticles for drug delivery. *Chin Chem Lett*. 2018;29:301–4.
- Zhang Q, Shen C, Zhao N, Xu FJ. Redox-responsive and drug-embedded silica nanoparticles with unique self-destruction features for efficient gene/drug codelivery. *Adv Func Mater*. 2017;27:1606229.
- Zhao S, Xu M, Cao C, Yu Q, Zhou Y, Liu J. A redox-responsive strategy using mesoporous silica nanoparticles for co-delivery of siRNA and doxorubicin. *J Mater Chem B*. 2017;5:6908–19.
- Chen X, Sun H, Hu J, Han X, Liu H, Hu Y. Transferrin gated mesoporous silica nanoparticles for redox-responsive and targeted drug delivery. *Colloids Surf B*. 2017;152:77–84.
- Lin JT, Du JK, Yang YQ, Li L, Zhang DW, Liang CL, Wang J, Mei J, Wang GH. pH and redox dual stimulate-responsive nanocarriers based on hyaluronic acid coated mesoporous silica for targeted drug delivery. *Mater Sci Eng C Mater Biol Appl*. 2017;81:478–84.
- Yuan F, Li JL, Cheng H, Zeng X, Zhang XZ. A redox-responsive mesoporous silica based nanopatform for in vitro tumor-specific fluorescence imaging and enhanced photodynamic therapy. *Biomater Sci*. 2017;6:96–100.
- Cheng B, He H, Huang T, Berr SS, He J, Fan D, Zhang J, Xu P. Gold nanoparticle gated mesoporous silica nanoparticle responsive to near-infrared light and redox potential as a theranostic platform for cancer therapy. *J Biomed Nanotechnol*. 2016;12:435–49.
- Li X, Zhao W, Liu X, Chen K, Zhu S, Shi P, Chen Y, Shi J. Mesoporous manganese silicate coated silica nanoparticles as multi-stimuli-responsive T-1-MRI contrast agents and drug delivery carriers. *Acta Biomater*. 2016;30:378–87.
- Zhao C, Shao L, Lu J, Zhao C, Wei Y, Liu J, Li M, Wu Y. Triple redox responsive poly(ethylene glycol)-polycaprolactone polymeric nanocarriers for fine-controlled drug release. *Macromol Biosci*. 2017;17:1600295.
- Ren G, Chen P, Tang J, Wang R, Duan S, Wang R, Xie Y, Zhang S. Construction and cellular uptake evaluation of redox-responsive docetaxel prodrug self-assembled nanoparticles. *Drug Dev Ind Pharm*. 2018;44:598–607.
- Klaikherd A, Nagamani C, Thayumanavan S. Multi-stimuli sensitive amphiphilic block copolymer assemblies. *J Am Chem Soc*. 2009;131:4830–8.

50. John JV, Uthaman S, Augustine R, Lekshmi KM, Park I-K, Kim I. Biomimetic pH/redox dual stimuli-responsive zwitterionic polymer block poly(L-histidine) micelles for intracellular delivery of doxorubicin into tumor cells. *J Polym Sci Part A Polym Chem*. 2017;55:2061–70.
51. Qin B, Liu L, Wu X, Liang F, Hou T, Pan Y, Song S. mPEGylated solanesol micelles as redox-responsive nanocarriers with synergistic anticancer effect. *Acta Biomater*. 2017;64:211–22.
52. Zhou Y, Wen H, Gu L, Fu J, Guo J, Du L, Zhou X, Yu X, Huang Y, Wang H. Aminoglucose-functionalized, redox-responsive polymer nanomicelles for overcoming chemoresistance in lung cancer cells. *J Nanobiotechnol*. 2017;15:87.
53. Koo AN, Lee HJ, Kim SE, Chang JH, Park C, Kim C, Park JH, Lee SC. Disulfide-cross-linked PEG-poly(amino acid)s copolymer micelles for glutathione-mediated intracellular drug delivery. *Chem Commun*. 2008;2008:6570–2.
54. Le CM, Thi HH, Cao XT, Kim G-D, Oh CW, Lim KT. Redox-responsive core cross-linked micelles of poly(ethylene oxide)-b-poly(furfuryl methacrylate) by diels-alder reaction for doxorubicin release. *J Polym Sci Part A Polym Chem*. 2016;54:3741–50.
55. Huang Y, Sun R, Luo Q, Wang Y, Zhang K, Deng X, Zhu W, Li X, Shen Z. In situ fabrication of paclitaxel-loaded core-crosslinked micelles via thiol-ene “Click” chemistry for reduction-responsive drug release. *J Polym Sci Part A Polym Chem*. 2016;54:99–107.
56. Ryu J-H, Chacko RT, Jiwpanich S, Bickerton S, Babu RP, Thayumanavan S. Self-cross-linked polymer nanogels: a versatile nanoscopic drug delivery platform. *J Am Chem Soc*. 2010;132:17227–35.
57. Zhang F, Gong S, Wu J, Li H, Oupicky D, Sun M. CXCR4-targeted and redox responsive dextrin nanogel for metastatic breast cancer therapy. *Biomacromol*. 2017;18:1793–802.
58. Ong W, Yang Y, Cruciano AC, McCarley RL. Redox-triggered contents release from liposomes. *J Am Chem Soc*. 2008;130:14739–44.
59. Mavuso S, Marimuthu T, Kumar P, Kondiah PPD, du Toit LC, Choonara YE, Pillay V. *in vitro*, *ex vivo*, and *in vivo* evaluation of a dual pH/redox responsive nanoliposomal sludge for transdermal drug delivery. *J Pharm Sci*. 2018;107:1028–36.
60. Kurtoglu YE, Navath RS, Wang B, Kannan S, Romero R, Kannan RM. Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery. *Biomaterials*. 2009;30:2112–21.
61. Schmitz T, Bravo-Osuna I, Vauthier C, Ponchel G, Loretz B, Bernkop-Schnürch A. Development and *in vitro* evaluation of a thioether-based nanoparticulate gene delivery system. *Biomaterials*. 2007;28:524–31.
62. Bernkop-Schnürch A. Strategies to overcome the polycation dilemma in drug delivery. *Adv Drug Deliv Rev*. 2018. <https://doi.org/10.1016/j.addr.2018.07.017>.
63. Hu X, Zhang Y, Xie Z, Jing X, Bellotti A, Gu Z. Stimuli-responsive polymer-somes for biomedical applications. *Biomacromol*. 2017;18:649–73.
64. Huo X, Gunduz U. Smart drug delivery systems in cancer therapy. *Curr Drug Targets*. 2018;19:202–12.
65. Pourseif MM. Molecular machineries of pH dysregulation in tumor microenvironment: potential targets for cancer therapy. *Bioimpacts Bi*. 2017;7:115–33.
66. Barar J, Omid Y. Dysregulated pH in tumor microenvironment check-mates cancer therapy. *Bioimpacts*. 2013;3:149–62.
67. Andresen TL, Thompson DH, Kaasgaard T. Enzyme-triggered nanomedicine: drug release strategies in cancer therapy. *Mol Membr Biol*. 2010;27:353.
68. Ulijn RV. Enzyme-responsive materials: a new class of smart biomaterials. *J Mater Chem*. 2006;16:2217–25.
69. Zhang X, Zhao Y, Cao L, Sun L. Fabrication of degradable lemon-like porous silica nanospheres for pH/redox-responsive drug release. *Sensors Actuators B Chem*. 2018;257:105–15.
70. Roy D, Cambre JN, Sumerlin BS. Future perspectives and recent advances in stimuli-responsive materials. *Prog Polym Sci*. 2010;35:278–301.
71. Zhang Q, Shen CN, Zhao N, Xu FJ. Redox-responsive and drug-embedded silica nanoparticles with unique self-destruction features for efficient gene/drug codelivery. *Adv Funct Mater*. 2017;27:1606229.
72. Ge Z, Liu S. Functional block copolymer assemblies responsive to tumor and intracellular microenvironments for site-specific drug delivery and enhanced imaging performance. *Chem Soc Rev*. 2013;42:7289.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

